A total of @ patients with chronic hepatitis B refractory to to combined therapy with lamivudine ( LAM ) and ADV were randomized to receive INF-@b monotherapy ( @ ( @ ) , three times a week ) ( group A ) or combined therapy with entecavir ( @ mg/day ) plus adefovir ( @ mg/day ) ( group B ) .